03:52 AM EDT, 07/31/2024 (MT Newswires) -- Inari Medical ( NARI ) reported late Tuesday its Q2 swung to a loss of $0.54 per diluted share from earnings of $0.04 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.26.

Revenue for the quarter ended June 30 was $145.8 million, compared with $119 million a year earlier.

Analysts surveyed by Capital IQ expected $144.1 million.

The company raised its full-year 2024 revenue guidance to $594.5 million to $604.5 million from the prior range of $592.5 million to $602.5 million. Analysts polled by Capital IQ expect $599.8 million.

Separately, the company appointed Kevin Strange to succeed Mitch Hill as chief financial officer. Strange is Inari's senior vice president of finance, accounting, strategy and business development.

Price: 43.99, Change: -8.12, Percent Change: -15.58